YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

News Blast

Aug 15, 2005

A recent New England Journal of Medicine article substantiated CepTor Corporation’s platform technology in the areas of Duchenne muscular dystrophy (DMD) and multiple sclerosis, verifying the role of calpain as a known causative in both conditions and touting calpain inhibition as a viable therapy. CepTor’s lead product, Myodur, targets DMD.

Albany Molecular Research Inc. (AMRI) announced a two-year research collaboration with the National Institute of Neurological Disorders and Stroke to develop treatments for spinal muscular atrophy, a degenerative neuromuscular disease. AMRI will provide fee-for-service medicinal chemistry lead optimization on target compounds, including design and synthesis of analogs and analysis of associated structure activity relationships.

San Diego-based Illumina began commercial shipment of its Sentrix Human-1 Genotyping BeadChip, which can interrogate more than 100,000 SNP loci per sample. This SNP content strategy is powered by Illumina’s Infinium assay, a genotyping method that  offers virtually unconstrained locus selection and scalable assay multiplexing.

View Next Related Story
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.